Table 3.
Estimated coverage [%(95%CI)]a of adolescents for MenACWY, Tdap, and HPV vaccines, 2008–2018
| 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall | |||||||||||
| MenACWY | 42.3 | 54.4 | 63.4 | 71.4 | 75.0 | 78.8 | 80.2 | 82.4 | 82.9 | 85.9 | 87.2 |
| (40.9, 43.8) | (53.2, 55.7) | (62.2, 64.7) | (70.4, 72.5) | (73.8, 76.1) | (77.7, 79.9) | (79.1, 81.3) | (81.4, 83.4) | (81.9, 83.9) | (84.9, 86.8) | (86.3, 88.1) | |
| Tdap | 40.8 | 55.6 | 68.7 | 78.2 | 84.6 | 86.0 | 87.6 | 86.4 | 88.0 | 88.7 | 88.9 |
| (39.3, 42.2) | (54.3, 56.8) | (67.5, 69.8) | (77.2, 79.1) | (83.7, 85.5) | (85.1, 87.0) | (86.7, 88.5) | (85.4, 87.3) | (87.1, 88.9) | (87.8, 89.6) | (88.1, 89.7) | |
| 1HPV (females) | 37.2 | 44.3 | 48.7 | 53.0 | 53.9 | 57.3 | 60.0 | 62.8 | 65.0 | 68.6 | 69.9 |
| (35.1, 39.3) | (42.4, 46.1) | (46.9, 50.5) | (51.4, 54.7) | (52.0, 55.7) | (55.4, 59.2) | (58.1, 61.8) | (61.0, 64.6) | (63.3, 66.8) | (66.9, 70.3) | (68.1, 71.7) | |
| 1HPV (males) | 1.4 | 8.3 | 20.8 | 34.6 | 41.7 | 49.8 | 56.0 | 62.6 | 66.3 | ||
| (1.0, 1.7) | (7.3, 9.2) | (19.3, 22.4) | (32.7, 36.5) | (39.9, 43.6) | (48.0, 51.5) | (54.3, 57.7) | (61.0, 64.2) | (64.6, 68.0) | |||
| 3HPV (females) | 17.9 | 26.7 | 32.0 | 34.8 | 33.4 | 37.6 | 39.7 | 41.9 | 43.0 | 43.9 | 37.9 |
| (16.3, 19.5) | (25.2, 28.2) | (30.3, 33.6) | (33.2, 36.4) | (31.7, 35.2) | (35.7, 39.6) | (37.8, 41.5) | (40.1, 43.7) | (41.1, 44.8) | (42.0, 45.9) | (36.1, 39.8) | |
| 3HPV (males) | 0.1 | 1.3 | 6.8 | 13.9 | 21.6 | 28.1 | 31.5 | 34.8 | 32.0 | ||
| (0.0, 0.1) | (1.0, 1.7) | (5.8, 7.8) | (12.5, 15.3) | (20.0, 23.2) | (26.5, 29.7) | (29.9, 33.1) | (33.2, 36.4) | (30.2, 33.9) | |||
| With a Recommendation | |||||||||||
| MenACWY | 67.8 | 76.2 | 80.2 | 81.9 | 85.0 | 88.1 | |||||
| (65.1, 70.4) | (74.1, 78.2) | (78.5, 81.9) | (80.3, 83.5) | (83.5, 86.6) | (86.5, 89.7) | ||||||
| Tdap | 47.6 | 61.5 | 74.3 | 81.9 | 88.5 | 89.7 | |||||
| (45.4, 49.7) | (59.6, 63.4) | (72.8, 75.8) | (80.7, 83.1) | (87.4, 89.6) | (88.7, 90.8) | ||||||
| 1HPV (females) | 57.5 | 59.4 | 61.7 | 63.8 | 64.3 | 65.6 | 69.2 | 70.8 | 73.0 | 73.8 | 74.3 |
| (54.6, 60.4) | (57.1, 61.8) | (59.3, 64.1) | (61.8, 65.8) | (62.0, 66.5) | (63.3, 67.8) | (67.2, 71.3) | (68.8, 72.7) | (71.2, 74.8) | (71.9, 75.7) | (72.3, 76.3) | |
| 1HPV (males) | 17.2 | 36.1 | 46.3 | 59.6 | 63.4 | 67.5 | 68.8 | 72.5 | 75.1 | ||
| (11.9, 22.5) | (31.8, 40.3) | (43.0, 49.5) | (56.8, 62.4) | (61.0, 65.7) | (65.1, 69.8) | (66.8, 70.9) | (70.6, 74.3) | (73.2, 77.0) | |||
| 3HPV (females) | 29.4 | 38.4 | 42.5 | 42.3 | 42.0 | 44.6 | 47.9 | 48.9 | 49.5 | 48.9 | 41.2 |
| (26.6, 32.2) | (36.1, 40.7) | (40.2, 44.8) | (40.2, 44.4) | (39.7, 44.2) | (42.3, 47.0) | (45.6, 50.2) | (46.8, 51.1) | (47.3, 51.7) | (46.7, 51.0) | (39.0, 43.3) | |
| 3HPV (males) | 0.9 | 6.3 | 15.4 | 25.6 | 34.4 | 39.9 | 40.6 | 41.7 | 37.7 | ||
| (0.1, 1.6) | (4.7, 7.9) | (13.0, 17.8) | (22.9, 28.4) | (31.8, 37.0) | (37.5, 42.2) | (38.4, 42.7) | (39.7, 43.8) | (35.4, 40.0) | |||
| Without a Recommendation | |||||||||||
| MenACWY | 30.9 | 41.7 | 53.1 | 63.9 | 67.7 | 73.1 | |||||
| (29.1, 32.7) | (40.0, 43.4) | (51.3, 54.8) | (62.4, 65.4) | (66.0, 69.4) | (71.5, 74.8) | ||||||
| Tdap | 35.6 | 49.0 | 62.8 | 74.3 | 81.1 | 82.2 | |||||
| (33.4, 37.8) | (47.1, 51.0) | (60.9, 64.7) | (72.7, 75.8) | (79.6, 82.6) | (80.3, 84.0) | ||||||
| 1HPV (females) | 18.1 | 24.1 | 33.1 | 37.6 | 35.3 | 39.6 | 35.8 | 40.4 | 39.7 | 47.4 | 49.8 |
| (15.6, 20.6) | (21.3, 27.0) | (30.2, 36.0) | (34.7, 40.5) | (32.1, 38.6) | (35.4, 43.7) | (31.8, 39.8) | (36.3, 44.4) | (35.3, 44.2) | (42.7, 52.2) | (45.2, 54.5) | |
| 1HPV (males) | 0.5 | 3.7 | 9.8 | 14.8 | 19.2 | 25.4 | 35.4 | 42.1 | 44.7 | ||
| (0.3, 0.7) | (2.9, 4.4) | (8.3, 11.3) | (12.6, 16.9) | (16.8, 21.7) | (22.8, 28.1) | (32.1, 38.7) | (38.3, 46.0) | (41.0, 48.4) | |||
| 3HPV (females) | 7.4 | 11.3 | 19.4 | 23.6 | 19.0 | 22.7 | 19.7 | 23.2 | 22.5 | 25.9 | 20.0 |
| (5.9, 9.0) | (9.8, 12.8) | (17.0, 21.8) | (20.9, 26.2) | (16.2, 21.7) | (18.7, 26.7) | (16.5, 22.7) | (19.4, 26.9) | (18.9, 26.0) | (21.4, 30.4) | (16.3, 23.7) | |
| 3HPV (males) | 0.03 | 0.6 | 3.0 | 4.9 | 8.3 | 11.7 | 16.2 | 19.4 | 18.1 | ||
| (0.0, 0.06) | (0.3, 0.8) | (2.1, 4.0) | (3.4, 6.3) | (6.4, 10.2) | (9.8, 13.6) | (13.6, 18.8) | (16.3, 22.6) | (15.0, 21.1) |
a. Estimates and 95% confidence intervals obtained from log-binomial regression models. Year to year increases were considered significant when their respective confidence intervals did not overlap.
MenACWY, quadrivalent meningococcal conjugate vaccine; Tdap, Tetanus-diphtheria-acellular pertussis vaccine; HPV, Human papillomavirus.